We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
15/12/2017 16:19 | This looks exciting | mbmiah | |
15/12/2017 15:49 | Worst performer to the best in a couple of hours :-D | philanderer | |
15/12/2017 12:27 | Good work being done or sure 👍 | philanderer | |
15/12/2017 11:02 | Hi Phil, hopefully bodes well for a range of conditions in the years ahead. | essentialinvestor | |
15/12/2017 10:58 | Morning EI , Pharma Times carrying this article: 'Shire and partners launch Irish haemophilia study' Shire, the Royal College of Surgeons Ireland (RCSI) and Science Foundation Ireland (SFI), in collaboration with the Irish Haemophilia Society, have initiated a new study that aims to better personalise the care of haemophilia patients. article: | philanderer | |
15/12/2017 09:47 | Yes agree. | essentialinvestor | |
15/12/2017 09:40 | EI I believe you are referring to this academic article published in nature - While it doesn’t impact shire directly, it shows that there is still plenty of room for the development of novel therapies. This particular article showcases the synthetic development of viruses which could be used to deliver genes in gene therapy, or small compounds in a tissue targeted manner. Exciting stuff for the industry as a whole | swedeee | |
15/12/2017 09:00 | I'm assuming the potential gene therapy breakthrough for hemophilia announced yesterday was not a Shire drug?. | essentialinvestor | |
15/12/2017 08:59 | This one's really turning into a right old pile of sh*te , toss of a coin whether to dump the whole lot now. Morning everyone :-) | philanderer | |
14/12/2017 20:11 | Shire's New Formulation of Oncaspar Gets Approval in Europe | philanderer | |
14/12/2017 17:36 | Shire plc : Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients through Innovative Personalized Treatment | philanderer | |
14/12/2017 10:19 | New Roche threat to Shire's hemophilia franchise? CEO Ornskov says he's not worried | philanderer | |
13/12/2017 15:23 | might resurrect my IG account! | toffeeman | |
13/12/2017 15:18 | Great for traders , no stamp duty ;-) | philanderer | |
13/12/2017 12:54 | There's never a dull day is there with Shire!. No position atm. Possible news due any day on their strstegic review, or whatever they term it. | essentialinvestor | |
13/12/2017 12:27 | Just can't hold above that 3750p. | philanderer | |
13/12/2017 09:18 | Last 6 weeks on the chart is looking like Bart Simpson's haircut ;-) | philanderer | |
13/12/2017 08:37 | Morning and a first test of 3750 already so looking for that to hold at the end of the day. | toffeeman | |
12/12/2017 16:15 | Surprised! | toffeeman | |
12/12/2017 15:02 | 3750p breached, seems to be holding | romeike | |
12/12/2017 14:16 | It just won't have it :-) | philanderer | |
12/12/2017 13:55 | Prediction - it gets to 3780 just before the US opens - and then tanks.... | toffeeman | |
12/12/2017 09:51 | 3800 would get me all excited. | ruethewhirl | |
11/12/2017 18:44 | 3750 seems to be a barrier at the moment | cflather2000 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions